<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580320</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-03740</org_study_id>
    <nct_id>NCT00580320</nct_id>
  </id_info>
  <brief_title>Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma</brief_title>
  <official_title>Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma.
      Weekly administration of the combination will prove to be feasible and tolerable at an
      appropriate dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to determine recommended phase II doses for the combination
      dacarbazine and bortezomib administered weekly.

      Secondary objectives are to determine the maximum tolerated dose combination and to observe
      anti-tumor activity in terms of response rate(s), duration of response, time to progression,
      and time on treatment (a measure of both antitumor activity and treatment tolerance).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by serious adverse events</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Melanoma</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Parathyroid Carcinoma</condition>
  <condition>Small Cell Carcinoma of the Lung</condition>
  <condition>Carcinoid Tumors</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dacarbazine + bortezomib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine and bortezomib</intervention_name>
    <description>Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2</description>
    <arm_group_label>A</arm_group_label>
    <other_name>bortezomib (velcade)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic diagnosis of cutaneous or mucosal melanoma, soft tissue sarcoma (STS), or
             an APUD (amine precursor uptake and decarboxylation) tumor. APUD tumors include
             parathyroid carcinoma, medullary carcinoma of the thyroid, small cell carcinoma of the
             lung, pheochromocytoma, islet cell tumors, carcinoid tumors, and malignant
             paraganglioma.

          -  Measurable or evaluable disease not appropriate for resection and/or radiation with
             curative intent. Patients with small cell carcinoma must have extended stage disease
             or, if limited stage disease, must have received at least one prior systemic therapy.

          -  Age 18 years or greater

          -  ECOG Performance Status 0 or 1

          -  Women must be post-menopausal, infertile as the result of a surgical procedure, or
             willing to use a medically accepted form of birth control (abstinence, hormonal
             contraceptive, intra-uterine device, diaphragm with spermicide, condon with
             spermicide) for the duration of study treatment. Men also must agree to use a
             medically accepted form of birth control for the duration of study treatment.

        Exclusion Criteria:

          -  Uncontrolled brain metastatic disease

          -  Platelet count &lt;100

          -  Absolute neutrophil count &lt;1.5

          -  Blood transfusion or hematopoietic growth factors for cytopenia within one month of
             enrollment.

          -  Calculated or measured (Cockcroft and Gault formula) creatinine clearance &lt;30
             mL/minute

          -  AST &gt; 3 times the upper limit of normal, unless elevation due to metastatic disease,
             in which case AST &gt; 5 times the upper limit of normal

          -  Bilirubin &gt; 2 mg/mL

          -  Grade 2 or greater peripheral neuropathy

          -  Hypersensitivity to bortezomib, boron, mannitol, or dacarbazine

          -  Pregnant or nursing

          -  Other investigational drugs within 14 days of enrollment

          -  Other medical or other condition(s) that in the opinion of the
             investigator/sub-investigator might compromise the objectives of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Poklepovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massey Cancer Center/Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618599/</url>
    <description>Publication</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>APUD tumor</keyword>
  <keyword>dacarbazine</keyword>
  <keyword>bortezomib</keyword>
  <keyword>velcade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Parathyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

